Apolipoprotein C3 as A Paradoxical Inhibitor of Platelet Aggregation and Thrombosis – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Waltraud C. Schrottmaier et al, adding:
”Elevated Levels of Apolipoprotein C3 Impair Platelet Function and Reduce Thrombosis
ApoC3, a known cardiovascular risk factor, paradoxically acts as a lipoprotein-derived inhibitor of platelet aggregation and thrombosis by modulating AKT and VASP signaling and disrupting actin cytoskeleton remodeling, potentially counterbalancing its proatherogenic effects in hyperlipidemia.”
Title: Elevated levels of apolipoprotein C3 impair platelet function and reduce thrombosis
Authors: Waltraud C. Schrottmaier, Julia B. Kral-Pointner, Marion Mussbacher, Manuel Salzmann, Bernhard Hochreiter, Anita Pirabe, Theresa Reiter, Sigrun Badrnya, Johannes A. Schmid, Ivo Volf, Alice Assinger
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 24, 2026, 16:38Chris Centeno: Can Platelet Concentration Be Back-Calculated from Blood Draw Volume as a Surrogate?
-
Mar 24, 2026, 16:33Gaetan Duport: The Next Challenge for Patient Involvement at EMA
-
Mar 24, 2026, 16:27ABL Tyrosine Kinase Inhibitors Linked to Arterial Thrombosis – Blood Journals Portfolio
-
Mar 24, 2026, 16:21Wolfgang Miesbach: Infections as a Trigger for Stroke in Young Adults
-
Mar 24, 2026, 16:19Sue Hill: How a Biomedical Scientist’s Curiosity is Improving Patient Care
-
Mar 24, 2026, 16:16Seema Dawood: Platelet Satellitism – An EDTA-Dependent Cause of Pseudothrombocytopenia
-
Mar 24, 2026, 16:16New WECARE Study Highlights the Real-World Challenges of Living with Hemophilia – WFH
-
Mar 24, 2026, 16:13Omar Alami: What Mentorship Within The Bleeding Disorder Community Meant to Me
-
Mar 24, 2026, 16:11Tiago Pina Cabral: Can Port Maintenance be Safely Extended to 24 Weeks After Treatment Completion?